{
    "clinical_study": {
        "@rank": "57196", 
        "arm_group": [
            {
                "arm_group_label": "Erlotinib 100mg", 
                "arm_group_type": "Experimental", 
                "description": "Erlotinib 100mg"
            }, 
            {
                "arm_group_label": "Erlotinib 150mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Erlotinib 150mg"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether 100mg erlotinib had similar effect\n      compared with 150mg erlotinib in NSCLC patients with EGFR mutation in China."
        }, 
        "brief_title": "Erlotinib 100mg or 150mg in Treating EGFR Mutation NSCLC Patients", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "NSCLC", 
            "Egfr Mutation"
        ], 
        "condition_browse": {
            "mesh_term": "Carcinoma, Non-Small-Cell Lung"
        }, 
        "detailed_description": {
            "textblock": "In China it was confirmed that 150mg Erlotinib was effective in NSCLC patients wtih EGFR\n      mutation, but reducing dose occurring in some patients because of the drug related\n      side-effects. So we investigate that in Chinese patients with EGFR mutation whether low dose\n      (100mg) Erlotinib had similar effect and low toxcities compared with standad dose (150mg)\n      Erlotinib."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. The histological diagnosis of small cell lung cancer;(phase IIIB and IV)\n\n          2. Sensitive mutation EGFR gene (18, 19 del, 21 L858R gene mutation) (mutation detection\n             method for the ARMS-PCR method, sequence method or Immunohistochemistry method)\n\n          3. Never accept the anti-tumor therapy or have received treatment in patients with\n             advanced illness patients;\n\n          4. Never used EGFR inhibitors;\n\n          5. Measurable disease by RECIST criteria;\n\n          6. Male or female patients >=18 years of age;\n\n          7. ECOG karnofsky performance 0~3, life expectancy is greater than 12 weeks;\n\n          8. Patient must be accessible for treatment and follow-up;-\n\n        Exclusion Criteria:\n\n          1. Previously used EGFR inhibitors\n\n          2. Mix ingredients in patients with squamous cell carcinoma, small cell lung cancer;\n\n          3. Allergic to erlotinib;\n\n          4. Non-measurable lesions\n\n          5. Pregnant or lactating women;\n\n          6. Other researchers believe that does not fit into the group"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "304", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02140333", 
            "org_study_id": "FAHG20130819", 
            "secondary_id": "GZMC201301"
        }, 
        "intervention": {
            "arm_group_label": [
                "Erlotinib 100mg", 
                "Erlotinib 150mg"
            ], 
            "description": "100mg vs. 150mg", 
            "intervention_name": "Erlotinib", 
            "intervention_type": "Drug", 
            "other_name": "tarceva"
        }, 
        "intervention_browse": {
            "mesh_term": "Erlotinib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "erlotinib", 
            "EGFR mutation"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "contact": {
                "email": "drjianxing.he@gmail.com", 
                "last_name": "jianxing he, PhD", 
                "phone": "86-20-83062821"
            }, 
            "facility": {
                "address": {
                    "city": "Guanzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510120"
                }, 
                "name": "Guangzhou medical university"
            }, 
            "investigator": {
                "last_name": "jianxing he, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 3 Study of Erlotinib 100mg or 150mg in Treating EGFR Mutation Patients With Non-small Cell Lung Cancer", 
        "other_outcome": {
            "measure": "Overall survival time of patients", 
            "safety_issue": "Yes", 
            "time_frame": "3 year after the first treatment"
        }, 
        "overall_contact": {
            "email": "drjianxing.he@gmail.com", 
            "last_name": "jianxing He, PhD", 
            "phone": "86-20-83062821"
        }, 
        "overall_contact_backup": {
            "email": "yayazhang2004@163.com", 
            "last_name": "yalei zhang, Dr.", 
            "phone": "86-20-83062821"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The PFS time of patients", 
            "safety_issue": "Yes", 
            "time_frame": "2 years after the first treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02140333"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The First Affiliated Hospital of Guangzhou Medical University", 
            "investigator_full_name": "Jianxing He", 
            "investigator_title": "The First Affiliated Hospital of Guangzhou Medical Univers", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "The objective response rate of disease", 
            "safety_issue": "Yes", 
            "time_frame": "Patients will be followed for an expected average of 6 months"
        }, 
        "source": "The First Affiliated Hospital of Guangzhou Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The First Affiliated Hospital of Guangzhou Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}